MARKET

ATHE

ATHE

Alterity Therapeutics Ltd
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.650
+0.010
+0.61%
After Hours: 1.650 0 0.00% 16:58 03/03 EST
OPEN
1.640
PREV CLOSE
1.640
HIGH
1.710
LOW
1.610
VOLUME
248.56K
TURNOVER
--
52 WEEK HIGH
5.15
52 WEEK LOW
0.2800
MARKET CAP
55.85M
P/E (TTM)
-2.3792
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Alterity to present at the 7th International Congress of Multiple System Atrophy
and , /PRNewswire/ -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), will present at the upcoming 7th International Congress of Multiple System Atrophy (MSA2021), to be held in a virtual format from .
PR Newswire - PRF · 5d ago
Alterity Therapeutics reports 1H results
Alterity Therapeutics (ATHE): 1H GAAP EPS of -A$0.65.Revenue of A$1.93M (+3.2% Y/Y)Press Release
Seekingalpha · 5d ago
Alterity surges on funding win for ATH434 development
Alterity Therapeutics shares jump ([[ATHE]] +18.7%) after it announces the award of a grant from The Michael J. Fox Foundation for Parkinson's Research to determine optimal dosing of its lead
Seekingalpha · 02/09 15:35
Alterity Therapeutics Announces $495K In Funding From Michael J. Fox Foundation For ATH434 Dose Optimization For Parkinson's Disease Clinical Trials
NEW YORK, Feb. 9, 2021 /PRNewswire/ -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company") has today announced the award of a grant from The Michael J. Fox
Benzinga · 02/09 13:55
Alterity Therapeutics announces funding from Michael J. Fox Foundation for ATH434 dose optimization for Parkinson's disease clinical trials
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced the award of a grant from The Michael J. Fox Foundation for Parkinson's Research to determine optimal dosing of its lead drug candidate ATH434 for Parkinson's ...
PR Newswire · 02/09 13:53
Alterity Therapeutics names Dr. David Stamler as CEO
Alterity Therapeutics ([[ATHE]] +1.8%) announces the appointment of Dr David Stamler to the role of Chief Executive Office effective immediately.Dr Stamler joined Alterity Therapeutics in June 2017 as Chief Medical
Seekingalpha · 01/07 15:49
Dr David Stamler Appointed CEO
, /PRNewswire/ -- The Board of Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") is pleased to announce the appointment of Dr to the role of Chief Executive Office effective immediately.
PR Newswire - PRF · 01/07 13:00
Dr David Stamler Appointed CEO
The Board of Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") is pleased to announce the appointment of Dr David Stamler to the role of Chief Executive Office effective immediately.
PR Newswire · 01/07 13:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ATHE. Analyze the recent business situations of Alterity Therapeutics Ltd through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ATHE stock price target is 4.000 with a high estimate of 4.000 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 22
Institutional Holdings: 1.12M
% Owned: 3.32%
Shares Outstanding: 33.85M
TypeInstitutionsShares
Increased
4
297.21K
New
1
185.84K
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.96%
Pharmaceuticals & Medical Research
-1.89%
Key Executives
Non-Executive Chairman
Geoffrey Kempler
Chief Executive Officer
David Stamler
Chief Financial Officer
Kathryn Andrews
Secretary
Phillip Hains
Non-Executive Director
Tristan Edwards
Non-Executive Director
Lawrence Gozlan
Non-Executive Director
David Sinclair
Non-Executive Independent Director
Peter Marks
Non-Executive Independent Director
Brian Meltzer
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About ATHE
Alterity Therapeutics Limited, formerly Prana Biotechnology Limited, is a development-stage medical biotechnology company. The Company is engaged in the research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer's disease, Huntington disease, Parkinson's disease and other neurological disorders. The Company's lead product candidates are PBT2 and PBT434. The Company's lead drug candidate PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. The Company also has advanced a drug candidate for Parkinson's disease and other movement disorders (PBT434) and brain cancer (PBT519), which are in pre-clinical toxicology testing. Its other applications for its therapies include certain cancers, age-related macular degeneration, Motor Neuron disease, Creutzfeldt-Jakob disease (the human variant of Mad Cow disease), and a range of orphan neurodegenerative disorders.

Webull offers kinds of Alterity Therapeutics Ltd (ADR) stock information, including NASDAQ:ATHE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATHE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATHE stock methods without spending real money on the virtual paper trading platform.